Wellington Management Group LLP grew its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 3.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 470,191 shares of the company's stock after purchasing an additional 15,542 shares during the quarter. Wellington Management Group LLP owned about 1.02% of Pacira BioSciences worth $8,858,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Caitlin John LLC boosted its position in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after purchasing an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after buying an additional 2,749 shares during the period. PNC Financial Services Group Inc. increased its position in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after buying an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Pacira BioSciences during the 4th quarter valued at $190,000. 99.73% of the stock is currently owned by institutional investors.
Pacira BioSciences Stock Down 0.2 %
Shares of PCRX stock traded down $0.05 during mid-day trading on Tuesday, hitting $24.92. The company's stock had a trading volume of 44,180 shares, compared to its average volume of 968,383. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -12.25 and a beta of 0.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $31.67. The business has a 50-day moving average price of $24.70 and a 200 day moving average price of $20.93.
Analyst Upgrades and Downgrades
Several analysts have weighed in on PCRX shares. Barclays raised their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. HC Wainwright upped their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, April 8th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $26.67.
Get Our Latest Stock Analysis on PCRX
About Pacira BioSciences
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Featured Articles
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
